medRxiv preprint doi: https://doi.org/10.1101/2020.04.06.20055665; this version posted April 11, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

Delivering oxygen-enriched CPAP respiratory support using a non-invasive ventilation device

Peter Culmer¹, Steven Ashton², Martin Latham², Stuart Murdoch³, David Brettle², Nikil Kapur¹

- 1. School of Mechanical Engineering, University of Leeds
- 2. Medical Physics and Engineering, Leeds Teaching Hospitals Trust
- 3. Anaesthesia and Intensive Care Medicine, Leeds Teaching Hospitals Trust

Corresponding Authors: P.R.Culmer@leeds.ac.uk , N.Kapur@leeds.ac.uk

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2, otherwise known as coronavirus (COVID-19)) pandemic has placed a rapid increase in demand on healthcare providers (HCPs) to provide respiratory support for patients with moderate to acute symptoms [1]. HCPs do not have sufficient ventilator provision to meet this surge in demand. Emerging clinical reports indicate that Continuous Positive Airway Pressure (CPAP) non-invasive ventilation can help patients with moderate symptoms avoid the need for invasive ventilation in intensive care [2-3], a change to the early impression that early intubation was indicated. Regulatory authorities such as the UK MHRA and US FDA have produced guidance to support rapid development, manufacture and approval of new ventilation systems which can be produced at scale [4]. However, the strains placed by the COVID-19 pandemic on international supply-chains may limit manufacturing capabilities. Here we report our team's investigation to adapt existing non-invasive ventilators (NIV) capable of delivering CPAP for use with oxygen to deliver enriched ventilation of 40%+ FiO2. Our intention is to maximise use of existing resources available to HCPs, as NIV and sleep apnoea (CPAP) machines are widely available, in order to deliver therapeutic benefit and potentially avoid the need for positive pressure ventilation.

The Nippy 3+ (BREAS Medical) was selected due to its robustness and widespread availability in the locality. In CPAP mode, the system generates $3-20 \text{ cmH}_20$ (0.3-2.0kPa) using an internal centrifugal fan to pressurise atmospheric air. This offers the possibility to entrain O₂ either at the system's low pressure air inlet, or in the pressurised air-stream near the ventilation mask as shown in Figure 1.



Figure 1. Provision of oxygen-enriched air during CPAP ventilation

We modified a standard Nippy 3+ system to allow entrainment of oxygen at the intake port and evaluated the efficacy of these two approaches. The system was configured to operate at a pressure of 10 cm H₂O with 5L/min oxygen flow, combined with a model lung operating at 30 bpm with tidal volume of 0.28L. An oxygen meter was used to measure the effective FiO2 inhaled by the patient. Our results showed that entrainment of oxygen at the low pressure intake brought only modest increases in FiO2 (ca. 35%) in comparison to entrainment near the mask which achieved significantly higher FiO2 (ca. 50%). The difference in performance can be attributed to the single-arm breathing circuit in which air-flow is reversed during the expiration phase and part of the air column is vented to atmosphere. This results in losses of oxygen when entraining at the air intake, but entrainment near the patient benefits from the pressurised air-column created between the patient and HEPA filter, which acts as a 'buffer' to preserve oxygen and avoid losses. Although this testing model precludes gas exchange, it works are the precludes the two approaches and should be the store of the s

is representative of the relative performance of these two configurations and suggests that relatively low flow-rates of oxygen can be used to obtain therapeutic FiO2 levels. The FiO2 can be readily altered by altering the oxygen flow-rate with reference to idealised dilution levels (e.g. 45% FiO2 for Air:O2 at 20:51/min, or 60% FiO2 for Air:O2 at 20:81/min). However, the ultimate FiO2 delivered by this system varies with respiratory function and is not explicitly controlled by the system. Rather it requires external monitoring by a suitably qualified healthcare professional based upon the patient's SpO2 level and vital signs.

In conclusion, positive pressure ventilators can provide an effective means to deliver CPAP with oxygen-enriched air for therapeutic intervention using standard equipment and fittings, whilst minimising the oxygen demands on hospital infrastructure when treating large numbers of patients. This enables rapid deployment to provide flexible treatment pathways which reduce the burden on ICU for HCPs that are facing surges in demand on ventilation during the COVID-19 pandemic.

Acknowledgements

We would like to thank our multidisciplinary team; Graham Brown, Sam Flint, Kevin Meloy, Mick China, James Naylor, Hardy Boocock and the numerous healthcare professionals at Leeds Teaching Hospitals (UK) who have helped make this research possible.

References

1. Critical care crisis and some recommendations during the COVID-19 epidemic in China, Xie et al, Intensive Care Medicine, 2 March 2020 (<u>https://doi.org/10.1007/s00134-020-05979-7</u>)

2. Guidance for the role and use of non-invasive respiratory support in adult patients with coronavirus (confirmed or suspected), NHS England and Improvement, 6 April 2020 (Version 3)

3. Managing the respiratory care of patients with COVID-19, Italian Thoracic Society (AIPO) and Italian Respiratory Society (SIP), 23 March 2020

4. Life saving breathing aid developed to keep COVID-19 patients out of intensive care, Online Article (<u>https://www.nihr.ac.uk/news/life-saving-breathing-aid-developed-to-keep-covid-19-patients-out-of-intensive-care/24542</u>), Accessed March 30, 2020